Loading…
Loading…
EQUITY / NASDAQ · XNCM
Dermata Therapeutics, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.1 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 1.1 USD · Volume 15,149
251 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -3,013,567 USD | -1,772,731 USD | — |
| Net income | -2,967,063 USD | -1,701,093 USD | — |
| Cash and cash equivalents | 4,412,764 USD | — | — |
| Total liabilities | 1,833,079 USD | — | — |
| Total equity | 3,487,720 USD | 5,614,251 USD | -37.88% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 201/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD | 2025 / Quarter 201/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 4,412,764 USD | — | — | 7,521,978 USD | 4,664,127 USD | — | — | — |
| Net incomeIncome statement | -2,967,063 USD | -4,814,769 USD | -1,847,706 USD | — | -1,691,989 USD | -5,696,669 USD | -1,701,093 USD | -4,004,680 USD |
| Operating profitIncome statement | -3,013,567 USD | -4,939,949 USD | — | — | -1,760,671 USD | -5,873,205 USD | -1,772,731 USD | -4,112,535 USD |
| Total assetsBalance sheet | 5,320,799 USD | — | — | 7,863,826 USD | 5,071,410 USD | — | — | — |
| Total equityBalance sheet | 3,487,720 USD | — | 6,413,003 USD | 6,223,380 USD | 3,960,102 USD | — | 5,614,251 USD | — |
| Total liabilitiesBalance sheet | 1,833,079 USD | — | — | 1,640,446 USD | 1,111,308 USD | — | — | — |
| Capital expendituresCash flow statement | — | 110,667 USD | — | — | — | — | — | — |
| Financing cash flowCash flow statement | — | 1,902,699 USD | — | — | — | 7,930,919 USD | — | 7,943,907 USD |
| Investing cash flowCash flow statement | — | -110,667 USD | — | — | — | — | — | — |
| Operating cash flowCash flow statement | — | -4,901,246 USD | — | -7,800,000 USD | — | -6,428,362 USD | — | -4,624,547 USD |
| Report source | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 08/11/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.